Имеет ли самостоятельное значение мутация в гене MYD88 l265p при диффузных В-крупноклеточных лимфомах?

1. Королева Д.А., Звонков Е.Е., Щецова О.О. и др. Безбиопсийная диагностика первичной диффузной В-крупноклеточной лимфомы центральной нервной системы. Гематология и трансфузиология. Гематология и трансфузиология. 2024;69(3):368-383. DOI: 10.35754/0234-5730-2024-69-3-368-383Х–Х. DOI: 10.35754/0234-5730-2024-69-3-00-00.

2. Netea M.G., Wijmenga C., O’Neill L.A. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol. 2012; 13(6): 535–42.

3. von Bernuth H, Picard C, Puel A, Casanova JL. Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans. Eur J Immunol. 2012; 42(12): 3126–35.

4. Niroula A., Sekar A., Murakami M., et al. Distinction of lymphoid and myeloid clonal hematopoiesis Nat. Med. 2021; 27(11): 1921–7. DOI: 10.1038/s41591-021-01521-4.

5. Treon S.P., Xu L., Guerrera M.L., Jimenez C., et al. Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020; 38: 1198–208. DOI: 10.1200/JCO.19.02314.

6. Schmidt J., Federmann B., Schindler N., et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015; 169(6): 795–803. DOI: 10.1111/bjh.13361.

7. Dogliotti I., Jimenez C., Varettoni M., et al. Diagnostics in Waldenstrom’s macroglobulinemia: a consensus statement of the European Consortium for Waldenstrom’s Macroglobulinemia. Leukemia. 2023; 37: 388–95. DOI: 10.1038/s41375-022-01762-3.

8. Martinez-Lopez A., Curiel-Olmo S., Mollejo M., et al. MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. Am J Surg Pathol. 2015; 39(5): 644–51. DOI: 10.1097/PAS.0000000000000411.

9. Parry M., Rose-Zerilli M.J., Ljungstrom V., et al. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. Clin Cancer Res. 2015; 21: 4174–83. DOI: 10.1158/1078-0432.CCR-14-2759.

10. Pillonel V., Juskevicius D., Ng C.K.Y., et al. High-throughput sequencing of nodal marginal zone lymphomas identifes recurrent BRAF mutations. Leukemia. 2015; 32: 2412–26. DOI: 10.1038/s41375-018-0082-4.

11. Nadeu F., Diaz-Navarro A., Delgado J., et al. Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. Ann Rev Pathol. 2020; 15: 149–77. DOI: 10.1146/annurev-pathm echdis-012419-032810.

12. Chapuy B., Stewart C., Dunford A.J., et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 2018; 24: 679–90. DOI: 10.1038/s41591-018-0016-8.

13. Schmitz R.; Wright G.W., Huang D.W., et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2018; 378: 1396–407. DOI: 10.1056/NEJMoa1801445.

14. Lacy S.E., Barrans S.L., Beer P.A., et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report. Blood. 2020; 135: 1759–71. DOI: 10.1182/blood.2019003535.

15. von Beck K., von Beck T., Ferreli P.B., et al. Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer J. 2023; 13(1): 5. DOI: 10.1038/s41408-022-00773-8.